Steel plate supplier

Who owns Bioxcel Therapeutics Inc Top stakeholders of

sec.gov

This is the initial public offering of shares of common stock of BioXcel Therapeutics,Inc.We are offering 5,000,000 shares of our common stock.No public market currently exists for our stock.We anticipate that the initial public offering price will be between $11.00 and $13.00 per share.Who owns Rapt Therapeutics Inc? Top stakeholders of RAPT Bioxcel Therapeutics Inc (BTAI) Constellation Pharmceticls I (CNST) Principia Biopharma Inc (PRNB) Gritstone Oncology Ord (GRTS) Allogene Therapeutics Inc (ALLO) Guardant Health Inc (GH) Orchard Therapeutics Plc ads (ORTX) Celldex Therapeutics Inc (CLDX) Crowdstrike Hldgs Inc cl a (CRWD) The Realreal Inc (REAL) Zoom Video Communications In cl a Who owns Bioxcel Therapeutics Inc? Top stakeholders of Top Holders and Investors of Bioxcel Therapeutics Stock.Find out who owns Bioxcel Therapeutics Inc,who bought BTAI this quarter,and who sold BTAI? Fund or Company Name Number of Shares Valued At Change in Shares As Of ; State Street Corporation 974.38k $51.65M 672% Jun 2020

What Kind Of Shareholder Owns Most TG Therapeutics,Inc

Aug 12,2019 Who owns Bioxcel Therapeutics Inc Top stakeholders of#0183;A look at the shareholders of TG Therapeutics,Inc.(NASDAQ:TGTX) can tell us which group is most powerful.Generally speaking,as a company grows,institutions will increase their ownership Top 10 Drug Discovery and Development SolutionBioXcel Therapeutics is a clinical-stage biopharmaceutical company that uses novel AI,to identify the next wave of medicines across neuroscience and immuno-oncology.They are focused on leveraging cutting-edge technology and innovative research to develop high-value therapeutics aimed at transforming patients lives.Title Vice President Human ResourcesLocation Greater New York City500+ connectionsBioXcel Therapeutics,Inc.DEF 14A Apr.6,2020 8:00 AM NOTICE IS HEREBY GIVEN that the Annual Meeting of Stockholders of BioXcel Therapeutics,Inc.,a Delaware corporation,will be held on Wednesday,May 20,2020,at

Some results are removed in response to a notice of local law requirement.For more information,please see here.Previous123456NextBioXcel Therapeutics Announces Initiation of a Phase 2

BioXcel Therapeutics,Inc.is a clinical stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology.BTI's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning Quarterly Report (10-q)Quarterly Report (10-q) - Bioxcel Therapeutics,Inc.BTAI.Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)BioXcel Therapeutics,Inc.is a clinical stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology.BioXcel's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine

Petr Matuska - Machine Learning Consultant - BioXcel

BioXcel Therapeutics Inc. Product and project IT management focused traineeship in stakeholder-driven environment of global agro company.Gaining experience in data analysis,process mapping,system design,continual service improvement,ITIL methodology (ITIL foundation certificate),negotiation with vendors,agile management (Scrum MODERNA,INC. Shareholders Board Members ManagersIts therapeutics and vaccine development programs span infectious diseases,oncology,cardiovascular diseases,and rare genetic diseases.It has created six modalities prophylactic vaccines,cancer vaccines,intratumoral immmuno-oncology,localized regenerative therapeutics,systemic secreted therapeutics and systemic intracellular therapeutics.Krishnan Nandabalan,Co-Founder at BioXcel Corp BioXcel Corp.is a major shareholder of BioXcel Therapeutics,Inc.(60.44 %).The company s ays this about itself BioXcel is a biopharmaceutical company pioneering the integration of big data analytics and machine learning-based artificial intelligence with drug development expertise to advance the next wave of medicines,impacting the

Kimberly Sheehan - Vice President Human Resources

BioXcel Therapeutics,Inc.is a clinical-stage biopharmaceutical company that utilizes novel artificial intelligence,or AI,to identify the next wave of medicines across neuroscience and immuno How Many BioXcel Therapeutics,Inc.(NASDAQ:BTAI)Apr 26,2020 Who owns Bioxcel Therapeutics Inc Top stakeholders of#0183;We note that hedge funds dont have a meaningful investment in BioXcel Therapeutics.BioXcel Corporation is currently the companys largest shareholder with 45% of shares outstanding.FMR LLC is the second largest shareholder with 4.5% of common stock,followed by DNCA Finance,holding 4.4% of the stock.Home - Intensity TherapeuticsIntensity Therapeutics @IntensityInc 31 Mar With the success of our first clinical trials,Intensity is excited to begin enrolling patients in phase 2 cohorts with cancers that are difficult to treat and historically nonresponsive to PD1/PDL1 antibodies alone.

Edited Transcript of BTAI.OQ earnings conference call or

Aug 14,2020 Who owns Bioxcel Therapeutics Inc Top stakeholders of#0183;Vimal D.Mehta,BioXcel Therapeutics,Inc.- Founder,CEO,President,Secretary Director [41] That's right.As you mentioned,these are quite aEdited Transcript of BTAI.OQ earnings conference call or Aug 14,2020 Who owns Bioxcel Therapeutics Inc Top stakeholders of#0183;Vimal D.Mehta,BioXcel Therapeutics,Inc.- Founder,CEO,President,Secretary Director [41] That's right.As you mentioned,these are quite aBioxcel HomeBioXcel Therapeutics,Inc.is a clinical stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology.BTI's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning

Bioxcel Home

BioXcel Therapeutics,Inc.is a clinical stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology.BTI's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning Bioxcel BioXcel Featured in Fierce BiotechAug 02,2017 Who owns Bioxcel Therapeutics Inc Top stakeholders of#0183;BioXcel Corporation has announced the launch of its first-in-class PharmGPS Oncology and Immuno-Oncology Suite,which uses big data technology to help biopharmaceutical companies and other stakeholders identify and prioritize the those immunotherapy candidates in their portfolios with the best potential to improve patient outcomes.Bioxcel BioXcel Featured in Fierce BiotechAug 02,2017 Who owns Bioxcel Therapeutics Inc Top stakeholders of#0183;BioXcel Corporation has announced the launch of its first-in-class PharmGPS Oncology and Immuno-Oncology Suite,which uses big data technology to help biopharmaceutical companies and other stakeholders identify and prioritize the those immunotherapy candidates in their portfolios with the best potential to improve patient outcomes.

BioXcel Therapeutics,Inc.(BTAI) investors to reap big

Sep 07,2020 Who owns Bioxcel Therapeutics Inc Top stakeholders of#0183;BioXcel Therapeutics,Inc.(NASDAQ:BTAI) has a beta value of 0 and has seen 508,269 shares traded in the last trading session.The company,currently valued at $917.67 Million,closed the last trade at $41.05 per share which meant it lost -$1.47 on the day or BioXcel Therapeutics' (BTAI) CEO Vimal Mehta on Q2 2020 Aug 14,2020 Who owns Bioxcel Therapeutics Inc Top stakeholders of#0183;BioXcel Therapeutics,Inc.(NASDAQ:BTAI) Q2 2020 Earnings Conference Call August 14,2020 8:30 AM ET Company Participants Vimal Mehta Chief Executive Officer Michael Stanton BioXcel Therapeutics Inc (NASDAQ:BTAI) Sees Significant Aug 20,2020 Who owns Bioxcel Therapeutics Inc Top stakeholders of#0183;BioXcel Therapeutics Inc (NASDAQ:BTAI) was the recipient of a significant growth in short interest during the month of August.As of August 14th,there was short interest totalling 2,810,000 shares,a growth of 30.1% from the July 30th total of 2,160,000 shares.Based on an average daily trading volume,of 611,400 shares,the days-to-cover ratio []

BioXcel Therapeutics Inc (NASDAQ:BTAI) Sees Large Decline

Jun 22,2020 Who owns Bioxcel Therapeutics Inc Top stakeholders of#0183;BioXcel Therapeutics Inc (NASDAQ:BTAI) was the recipient of a significant decrease in short interest in June.As of June 15th,there was short interest totalling 674,800 shares,a decrease of 13.6% from the May 31st total of 781,000 shares.Approximately 6.4% of the shares of the company are sold short.Based on an average daily []BioXcel Therapeutics Inc (NASDAQ:BTAI) Receives Consensus Vanguard Group Inc.raised its position in shares of BioXcel Therapeutics by 17.5% during the second quarter.Vanguard Group Inc.now owns 576,588 shares of the company's stock valued at $30,564,000 after buying an additional 86,019 shares during the last quarter.BioXcel Therapeutics Announces Primary and Secondary BioXcel Therapeutics,Inc.BioXcel Therapeutics,Inc.is a clinical stage biopharmaceutical company focused on drug development that utilizes artificial intelligence to identify improved therapies in neuroscience and immuno-oncology.

BioXcel Therapeutics Announces Primary and Secondary

BioXcel Therapeutics,Inc.BioXcel Therapeutics,Inc.is a clinical stage biopharmaceutical company focused on drug development that utilizes artificial intelligence to identify improved therapies in neuroscience and immuno-oncology.BioXcel Therapeutics Announces Primary and Secondary BioXcel Therapeutics,Inc.BioXcel Therapeutics,Inc.is a clinical stage biopharmaceutical company focused on drug development that utilizes artificial intelligence to identify improved therapies in neuroscience and immuno-oncology.BioXcel Therapeutics Announces Initiation of a Phase 2 BioXcel Therapeutics,Inc.is a clinical stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology.BTI's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning

BioXcel Therapeutics (NASDAQ:BTAI) Trading Up 13.5%

BioXcel Therapeutics Inc (NASDAQ:BTAI) shares were up 13.5% on Wednesday .The company traded as high as $47.92 and last traded at $46.24.Approximately 367,700 shares traded hands during trading,a decline of 41% from the average daily volume of 624,072 shares.The stock had previously closed at $40.75.A number of equities research analysts []BioXcel Therapeutics (NASDAQ:BTAI) Shares Gap Down toFeb 23,2020 Who owns Bioxcel Therapeutics Inc Top stakeholders of#0183;Strs Ohio raised its position in BioXcel Therapeutics by 431.3% during the third quarter.Strs Ohio now owns 8,500 shares of the companys stock valued at $59,000 after acquiring an additional 6,900 shares in the last quarter.American International Group Inc.raised its position in shares of BioXcel Therapeutics by 14.2% in the fourth quarter.BioXcel Therapeutics (NASDAQ:BTAI) Shares Gap Down toFeb 23,2020 Who owns Bioxcel Therapeutics Inc Top stakeholders of#0183;Strs Ohio raised its position in BioXcel Therapeutics by 431.3% during the third quarter.Strs Ohio now owns 8,500 shares of the companys stock valued at $59,000 after acquiring an additional 6,900 shares in the last quarter.American International Group Inc.raised its position in shares of BioXcel Therapeutics by 14.2% in the fourth quarter.

Aman Kant - Business Profile InveniAI Corporation

Sep 17,2019 Who owns Bioxcel Therapeutics Inc Top stakeholders of#0183;InveniAI Who owns Bioxcel Therapeutics Inc Top stakeholders ofCorporation,a wholly owned subsidiary and technology spin-out of BioXcel Corporation,has pioneered the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across healthcare and other industries.About Us Frequency TherapeuticsAbout.We are a clinical-stage biotechnology company focused on harnessing the bodys innate biology to repair or reverse damage caused by a broad range of degenerative diseases.5 AI Biotech Stocks to Bet On Now InvestorPlaceJun 05,2018 Who owns Bioxcel Therapeutics Inc Top stakeholders of#0183;Biotech BioXcel Therapeutics Inc (NASDAQ:BTAI) is on the hunt for the next wave of neuroscience and immuno-oncology medicines.BTAI uses AI

5 AI Biotech Stocks to Bet On Now InvestorPlace

Jun 05,2018 Who owns Bioxcel Therapeutics Inc Top stakeholders of#0183;Biotech BioXcel Therapeutics Inc (NASDAQ:BTAI) is on the hunt for the next wave of neuroscience and immuno-oncology medicines.BTAI uses AI12345NextBioXcel Therapeutics (NASDAQ:BTAI) Shares Down 8% Sep 03,2020 Who owns Bioxcel Therapeutics Inc Top stakeholders of#0183;Shares of BioXcel Therapeutics Inc (NASDAQ:BTAI) fell 8% during mid-day trading on Thursday .The stock traded as low as $41.91 and last traded at $42.52.1,199,100 shares changed hands during trading,an increase of 92% from the average session volume of 624,528 shares.The stock had previously closed at $46.24.Several research firms have []

Leave A Message

If you need a quotation, please send us your detailed requirements and we will reply to you within 24 hours.

Looking for steel stock and quoted price?